UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 4, 2022

Hoth Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

1 Rockefeller Plaza, Suite 1039

New York, New York 10020

(Address of principal executive offices, including ZIP code)

(646) 756-2997

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Hoth Therapeutics, Inc. (the “Company”) filed a Patent Cooperation Treaty (“PCT”) patent application for the use of one of its current portfolio therapeutics to treat and prevent Alzheimer’s disease on February 22, 2022 and received confirmation of the filing of the PCT patent application on April 4, 2022. The positive scientific data included in the PCT patent application were generated pursuant a Scientific Research Agreement between the Company and Washington University in St. Louis, Missouri.

Alzheimer’s disease (“AD”) is a progressive neurodegenerative disorder that is associated with the destruction of higher brain structures such as those involved in memory and cognition. The disease leads to deficits in cognitive function and declines in memory, learning, language, and in the ability to perform intentional and purposeful movements. AD is also accompanied by concomitant behavioral, emotional, interpersonal, and social deterioration. These cognitive and behavioral deficits render living difficult. Late-stage AD patients are often unable to speak, comprehend language, and handle their own basic personal care, eventually requiring full-time care and supervision, and are often dependent on family members and nursing homes. AD is the leading cause of senile dementia and is predicted to increase in prevalence as the proportion of elderly persons in the population grows. According to Sloane et al., Annu Rev Public Health. 2002;23:213-31, “The Public Health Impact of Alzheimer’s Disease, 2000-2050: Potential Implication of Treatment Advances”, the total number of persons with AD is predicted to increase at least threefold between 2000 and 2050, rendering AD a world-wide public health problem. Clinical detection, management, and treatment of AD remain largely inadequate. There is still an unmet need for effective methods to prevent and treat AD. 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

2